By Sam Boughedda
Investing.com — Equity of Adicet Bio Inc (NASDAQ :) soared in trading Monday after reporting positive interim data from dose escalation in a phase I trial of a potential treatment for B-cell non-Hodgkin’s lymphoma. ..
Adicet shares were open and hit a high of $ 13.80 and are currently trading around $ 12.88, up 31%.
The company explained that as of November 22, at the time of the data cutoff, six patients were enrolled in a drug trial called ADI-001. The first two patients enrolled did not reach the rating, but three of the four evaluable patients achieved a response that included two complete responses and one partial response. ..
“The data so far suggest that ADI-001 is clinically very active. We will report additional data in the first half of 2022, revealing the potential of a gamma-delta CAR T cell platform for patients. We look forward to rapidly advancing the pipeline to maximize its potential, commented Chen Schor, President and CEO of Adicet Bio.
Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Adicet Bio Stock jumps into the potential of investing.com to treat non-Hodgkin’s lymphoma
Source link Adicet Bio Stock jumps into the potential of investing.com to treat non-Hodgkin’s lymphoma